Online citations, reference lists, and bibliographies.
← Back to Search

Lobectomy Versus Stereotactic Body Radiotherapy In Healthy Patients With Stage I Lung Cancer.

J. Rosen, M. Salazar, Z. Wang, J. Yu, R. Decker, A. Kim, F. Detterbeck, D. Boffa
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES Stereotactic body radiotherapy is an effective treatment for patients with early-stage non-small cell lung cancer who are not healthy enough to undergo surgery; however, the relative efficacy versus surgery in healthy patients is unknown. The National Cancer Database contains information on patient health and eligibility for surgery, allowing the long-term survival associated with lobectomy and stereotactic body radiotherapy to be compared in healthy patients with clinical stage I disease. METHODS The National Cancer Database was queried for patients who underwent lobectomy or stereotactic body radiotherapy for clinical stage I lung cancer between 2008 and 2012. Healthy patients were selected by excluding patients not offered surgery because of health-related reasons and only including patients documented to be free of comorbidities. RESULTS A total of 13,562 comorbidity-free patients with clinical stage I lung cancer treated with lobectomy were compared with 1781 patients treated with stereotactic body radiotherapy. Time-stratified Cox proportional hazards models found lobectomy to be associated with a significantly better outcome than stereotactic body radiotherapy for both T1N0M0 tumors (hazard ratio, 0.38; 95% confidence interval, 0.33-0.43; P < .001) and T2N0M0 tumors 5 cm or less (hazard ratio, 0.38; confidence interval, 0.31-0.46; P < .001). In a propensity-matched analysis of 1781 pairs, lobectomy remained superior to stereotactic body radiotherapy (5-year survival 59% vs 29%, P < .001). Furthermore, when the subset of stereotactic patients who had refused a recommended surgery (n = 229) were propensity matched to lobectomy patients, lobectomy was associated with improved survival (5-year survival 58% vs 40%, P = .010). CONCLUSIONS Among healthy patients with clinical stage I non-small cell lung cancer in the National Cancer Database, lobectomy is associated with a significantly better outcome than stereotactic body radiotherapy. Further study is warranted to clarify the comparative effectiveness of surgery and stereotactic body radiotherapy across various strata of patient health.
This paper references
10.1016/S1470-2045(15)70168-3
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
J. Chang (2015)
10.1097/JTO.0b013e318260e00d
A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided Radiotherapy
I. Grills (2012)
10.1097/JTO.0000000000000680
Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy
V. Puri (2015)
10.1001/jama.2010.261
Stereotactic body radiation therapy for inoperable early stage lung cancer.
R. Timmerman (2010)
10.1378/CHEST.109.5.1199
Cell type accuracy of bronchial biopsy specimens in primary lung cancer.
J. J. Cataluña (1996)
10.1245/s10434-014-3860-x
Survival and Treatment of Non-small Cell Lung Cancer Stage I–II Treated Surgically or with Stereotactic Body Radiotherapy: Patient and Tumor-Specific Factors Affect the Prognosis
S. Mokhles (2014)
10.1016/j.athoracsur.2012.04.059
Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections.
D. Boffa (2012)
10.1016/j.lungcan.2015.05.002
Racial disparities in the use of SBRT for treating early-stage lung cancer.
C. Corso (2015)
10.1200/JCO.2013.31.15_SUPPL.7523
RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients.
R. Timmerman (2013)
10.1016/j.athoracsur.2014.07.007
Predictors of mortality after surgical management of lung cancer in the National Cancer Database.
J. Rosen (2014)
10.1056/NEJMOA031644
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
R. Arriagada (2004)
10.1097/JTO.0b013e3181c814e7
Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation
J. Douillard (2010)
10.1378/CHEST.117.2.374
Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA.
M. V. van Rens (2000)
10.1002/cncr.29359
Comparative effectiveness of surgery and radiosurgery for stage I non–small cell lung cancer
J. Yu (2015)
10.1093/jncimonographs/lgu022
Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death.
Nadia Howlader (2014)
10.1200/JCO.2008.16.4855
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
G. Strauss (2008)
10.1136/jcp.53.7.537
Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category
S. L. Edwards (2000)
10.1200/JCO.2007.13.9030
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
J. Pignon (2008)
10.1200/JCO.2009.25.0928
Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
I. Grills (2010)
10.1016/j.ijrobp.2011.06.2003
Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
F. Lagerwaard (2012)
10.1016/j.ijrobp.2009.07.1751
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
H. Onishi (2011)
10.1016/0003-4975(95)00537-U
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.
R. Ginsberg (1995)
10.1001/jama.2015.13480
The Propensity Score.
J. Haukoos (2015)
10.1016/j.ijrobp.2014.05.055
Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis.
X. Zheng (2014)
10.1016/j.jtcvs.2009.12.054
Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
T. Crabtree (2010)
10.1097/JTO.0b013e3182614bf3
Stereotactic Body Radiotherapy for Central Lung Tumors
Bryan Rowe (2012)
10.1378/chest.12-2355
Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
G. Silvestri (2013)
10.1016/j.athoracsur.2009.10.034
Long-term survival after video-assisted thoracic surgery lobectomy for primary lung cancer.
K. Yamamoto (2010)
10.1016/j.ijrobp.2013.12.050
No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.
S. Stanić (2014)
10.1016/j.athoracsur.2014.09.033
Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery.
J. Hancock (2015)
10.1093/annonc/mdt026
Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis.
N. Verstegen (2013)
10.1016/j.ijrobp.2012.07.2354
Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly.
S. Shirvani (2012)



This paper is referenced by
10.1245/s10434-018-07130-9
What’s Lost in What’s Missing: A Thoughtful Approach to Missing Data in the National Cancer Database
D. Boffa (2018)
10.1016/j.jtcvs.2017.04.020
The value of salvage surgery after stereotactic body radiotherapy failure: A sticky conundrum.
B. Wei (2017)
10.1016/j.semradonc.2017.03.001
Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
J. Shah (2017)
10.1093/ejcts/ezx410
The great debate flashes: surgery versus stereotactic body radiotherapy as the primary treatment of early-stage lung cancer
W. Weder (2018)
10.1002/cam4.2005
A system‐based intervention to reduce Black‐White disparities in the treatment of early stage lung cancer: A pragmatic trial at five cancer centers
S. Cykert (2019)
10.21037/VATS.2018.03.01
Stereotactic body radiotherapy for early-stage non-small cell lung cancer: a surgical perspective on the American Society for Radiation Oncology Guidelines
C. Cao (2018)
10.21037/JTD.2018.10.35
Surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer: review of meta-analyses.
M. Hamaji (2019)
10.1007/s00595-017-1536-4
Surgery or stereotactic body radiotherapy for elderly stage I lung cancer? A propensity score matching analysis
T. Miyazaki (2017)
10.1016/j.jtcvs.2019.09.050
Commentary: Robotic anatomic lung resection: Raising the bar of our expectations in treating lung cancer.
A. Abbas (2019)
10.1200/JOP.2016.018309
Curing Early-Stage Lung Cancer: Is There an Easy Way Out?
E. Warner (2017)
10.2147/OTT.S138701
Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis
Ming Li (2017)
10.1016/J.JTCVS.2019.03.063
Commentary: Simple math is not so straightforward with stereotactic body radiotherapy for colorectal carcinoma metastases.
William H. Gray (2019)
10.1177/1533033818807431
Salvage Pulmonary Operations Following Stereotactic Body Radiotherapy for Small Primary and Metastatic Lung Tumors: Evaluation of the Operative Procedures
Hiroshi Hamakawa (2018)
10.1038/s41598-019-57321-x
Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung
Yuko Tashima (2020)
10.1016/j.jtcvs.2016.04.016
Surgery versus stereotactic body radiation therapy for operable stage I non-small cell lung cancer: Can we achieve equipoise?
M. Onaitis (2016)
Abstract. A standard treatment for patients with early-stage non-small cell lung cancer (NSCLC) who undergo surgery, and subsequently develop local failure or intrathoracic oligo-
S. Aoki (2020)
10.1016/j.jtcvs.2017.03.142
Salvage pulmonary resection after stereotactic body radiotherapy: A feasible and safe option for local failure in selected patients
M. Antonoff (2017)
10.21037/jtd.2018.04.52
Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances.
Nikhil T. Sebastian (2018)
10.1016/J.RADONC.2019.01.027
Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
B. Kann (2019)
10.1001/jamaoncol.2016.6905
Using the National Cancer Database for Outcomes Research: A Review
D. Boffa (2017)
10.1016/j.lungcan.2018.07.033
Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.
J. P. Harris (2018)
10.1016/j.cllc.2020.04.017
Oncologic Outcomes of Surgery Versus SBRT for Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
M. IJsseldijk (2020)
10.21037/jtd.2017.12.39
Sarcopenia is a predictor of outcomes after lobectomy.
J. A. Miller (2018)
10.1016/j.jtcvs.2018.11.139
Do the surgical results in the National Lung Screening Trial reflect modern thoracic surgical practice?
M. Kamel (2019)
10.1055/S-0042-122321
Prognose des Lungenkarzinoms: Lobektomie und stereotaktische Radiotherapie im Vergleich
Horst A. Groß (2017)
10.5152/EURJTHER.2018.1006
Which is the Best in Early Lung Cancer; Surgery or Stereotactic Body Radiation Therapy?
H. Kutlay (2018)
10.21037/jovs.2016.11.03
Video-assisted thoracic surgery and open chest surgery in lung cancer treatment: present and future.
F. Detterbeck (2016)
10.1016/j.jtcvs.2017.02.065
A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer
B. Yerokun (2017)
10.3389/fonc.2020.585709
Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Body Radiotherapy Treatment for Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matching Analysis
Bai-qiang Dong (2020)
Proton beam therapy in non-small cell lung cancer : state of the art Hideyuki
Harada (2017)
10.1016/j.jtcvs.2018.08.075
A systematic review and meta‐analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer
C. Cao (2019)
Radiothérapie stéréotaxique pulmonaire des tumeurs primitives bronchiques : étude de cohorte rétrospective de 136 patients et 156 lésions et impact de la biologie moléculaire
A. Suissa (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar